A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/21/2019
Start Date:September 6, 2018
End Date:March 3, 2022
Contact:Reference Study ID Number: WO40181 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. and Canada)

Use our guide to learn which trials are right for you!

A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of
venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+,
HER2-negative, inoperable, locally advanced or MBC who experienced disease recurrence or
progression during or after treatment with CDK4/6i therapy for at least 8 weeks.


Inclusion Criteria:

- Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive
carcinoma of the breast. ER+, HER2- negative invasive carcinoma of the breast with
evaluable sample for BCL-2 IHC value at the time of screening. Participants who were
originally diagnosed with HER2-positive breast cancer that converted to HER2-negative
MBC are not eligible.

- Evidence of metastatic or locally advanced disease not amenable to surgical or local
therapy with curative intent

- Be postmenopausal or pre- or perimenopausal women amenable to being treated with the
luteinizing hormone-releasing hormone (LHRH) agonist goserelin

- Participants must not have received more than two prior lines of hormonal therapy in
the locally advanced or metastatic setting. In addition, at least one line of
treatment must be a CDK4/6i AND participants must have experienced disease recurrence
or progression during or after CDK4/6i therapy, which must have been administered for
a minimum of 8 weeks prior to progression.

- Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and
treatment with cytotoxic chemotherapy is not indicated at the time of entry into the
study, as per national or local treatment guidelines

- Women of childbearing potential (i.e., not postmenopausal for at least 12 months or
surgically sterile) must have a negative serum pregnancy test result at screening,
within 14 days prior to the first study drug administration

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use non-hormonal contraceptive methods with a failure
rate of <1% per year during the treatment period and for 28 days after the last dose
of study drug. Women must refrain from donating eggs during this same period.

- Willing to provide tumor biopsy sample

- Have at least one measurable lesion via RECIST v1.1

- Have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1

- Have adequate organ and marrow function

- Have a life expectancy > 3 months

- To full fill the coagulation requirements for patient with or without therapeutic
anticoagulation

Exclusion criteria:

- Prior treatment with fulvestrant or other selective estrogen receptor degraders
(SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2

- Pregnant, lactating, or intending to become pregnant during the study

- Known untreated or active Central Nervous System (CNS) metastases (progressing or
requiring anticonvulsants or corticosteroids for symptomatic control

- Prior chemotherapy in the locally advanced or metastatic setting regardless of the
duration of the treatment.

- Any anti-cancer therapy received within 21 days of the first dose of study drug,
including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic
vaccines, or other investigational therapy. (Radiotherapy with palliative intent to
non-target sites is allowed).

- Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1
Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be
followed for determination of a response) or prior radiotherapy to > 25% of bone
marrow

- Current severe, uncontrolled, systemic disease (e.g., clinically significant
cardiovascular, pulmonary, metabolic or infectious disease

- Any major surgery within 28 days of the first dose of study drug or anticipation of
the need for major surgery during the course of study treatment

- Consumption of one or more of the following within 3 days prior to the first dose of
study drug: Grapefruit or grapefruit products; Seville oranges including marmalade
containing Seville oranges; Star fruit (carambola)

- Administration within 7 days prior first dose of study treatment of Steroid therapy
for anti-neoplastic intent, Strong or moderate CYP3A inhibitors or Strong or moderate
CYP3A inducers

- Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an
equivalent dose of other anti-inflammatory corticosteroids)

- Known infection with (human immunodeficiency virus) HIV or human T-cell leukemia virus
1

- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
(excluding fungal infections of nail beds) at study enrollment, or any major episode
of infection requiring treatment with IV antibiotics or hospitalization (relating to
the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).

- Participants who are positive for HCV antibody must be negative for HCV by PCR to be
eligible for study participation. Participants with a past or resolved hepatitis B
virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis
B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These
participants must be willing to undergo monthly DNA testing

- Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV)
antibody at screening

- Active HCV infection, defined as having a positive HCV antibody test at screening

- History of other malignancies within the past 5 years except for treated skin basal
cell carcinoma, squamous cell carcinoma, non-malignant melanoma <= 1.0 mm without
ulceration, localized thyroid cancer, or cervical carcinoma in-situ

- Administration of a live, attenuated vaccine within 4 weeks prior to initiation of
study treatment or anticipation of need for such a vaccine during the study

- Cardiopulmonary dysfunction

- Other medical or psychiatric conditions that, in the opinion of the investigatory, may
interfere with the participant's participation in the study

- Inability or unwillingness to swallow pills or receive intramuscular (IM) injections

- History of malabsorption syndrome or other condition that would interfere with enteral
absorption

- History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or
active bowel inflammation (e.g., diverticulitis)

- Concurrent hormone replacement therapy

- Inability to comply with study and follow-up procedures

- History or active cardiopulmonary dysfunction

- Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to
any of the excipients.
We found this trial at
22
sites
Houston, Texas 77090
?
mi
from
Houston, TX
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
5323 Harry Hines Blvd
Dallas, Texas 75235
(214) 648-3111
Univ of Texas, Southwestern Med Ctr of Dallas The story of UT Southwestern Medical Center...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Ashland, Kentucky 41101
?
mi
from
Ashland, KY
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts 01923
?
mi
from
Boston, MA
Click here to add this to my saved trials
1190 East Newport Center Drive
Deerfield Beach, Florida 33442
?
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
(425) 297-5500
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
?
mi
from
Everett, WA
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
La Jolla, California 92037
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Lincoln, Nebraska 68506
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
340 Kennestone Hospital Boulevard
Marietta, Georgia 30060
?
mi
from
Marietta, GA
Click here to add this to my saved trials
800 E 28th St
Minneapolis, Minnesota 55407
(612) 863-4000
Abbott Northwestern Hospital Our hospital has a long and proud history as a health care...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
North Sydney,
Click here to add this to my saved trials
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Phoenix, Arizona
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
1621 South Minnesota Avenue
Sioux Falls, South Dakota 57105
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials